Introduction
P-glycoprotein is one of the drug transporters that determine the uptake and efflux of a range of drugs. This process affects their plasma and tissue concentrations and ultimately their final effects. P-glycoprotein functions as a transmembrane efflux pump, pumping its substrates from inside to outside the cell. Drugs which induce or inhibit P-glycoprotein can interact with other drugs handled by the pump.
Pharmacology
P-glycoprotein was first described in tumour cells. These cells had over-expression of P-glycoprotein which reduced the access of cytotoxic drugs. As this made the tumours resistant to various anticancer drugs, P-glycoprotein was also known as multidrug resistance protein 1. P-glycoprotein is also expressed in a variety of normal, non-tumorous tissues with excretory functions (small intestine, liver and kidney) 1 and at blood-tissue barriers (blood-brain barrier, blood-testis barrier and placenta). 2 Along with the cytochrome P450 (CYP) family of enzymes, concomitant expression of P-glycoprotein is believed to be an important evolutionary adaptation against potentially toxic substances. As an efflux transporter it limits the bioavailability of orally administered drugs by pumping them back into the lumen. This promotes drug elimination into the bile and urine and protects a number of tissues such as the brain, testis, placenta and lymphocytes. The substrates for P-glycoprotein are a broad variety of structurally diverse compounds. This article has a continuing professional development activity for pharmacists available at www.australianprescriber.com/ continuingprofessional development
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Concomitant administration of loperamide and a potent P-glycoprotein inhibitor, such as verapamil, may be associated with respiratory depression. This potentially dangerous central nervous system effect from such a widely used and easily accessible drug is of great interest. It raises safety concerns but suggests that inhibiting P-glycoprotein could be a novel strategy to overcome the blood-brain barrier to increase drug delivery to the brain. 8 
Digoxin
Induction or inhibition of intestinal P-glycoprotein appears to be a major mechanism underlying drug interactions that lead to reduced or elevated digoxin concentrations. Rifampicin and St John's wort induce P-glycoprotein and thereby decrease concentrations of digoxin.
HIV-1 protease inhibitors
The effective treatment of HIV may be hindered by P-glycoprotein located in cell membranes. Potential mechanisms include the following:
• intestinal P-glycoprotein limits the absorption of HIV protease inhibitors
• HIV protease inhibitors are good P-glycoprotein substrates, 9 so this limits their transfer across the blood-brain barrier, which can contribute to viral persistence and reduced effectiveness
• P-glycoprotein is also expressed in CD4 cells, the major target of anti-HIV drugs.
Dabigatran
As dabigatran etexilate is a substrate of P-glycoprotein, there is potential for drug interactions involving drugs acting on P-glycoprotein. Inhibitors of P-glycoprotein such as ketoconazole, amiodarone, verapamil, ticagrelor and clarithromycin may increase the peak plasma concentrations of dabigatran, and subsequently lead to a significantly increased risk of severe haemorrhage.
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Conclusion
P-glycoprotein is an efflux transporter pump present in many organs and plays an important role in drug transport. Expression of P-glycoprotein can have important effects on drug absorption, distribution and elimination. Although interactions with drug transporters can be clinically insignificant, an awareness of potential transporter-related drug-drug be altered when co-administered with compounds which inhibit or induce P-glycoprotein. 3 The substrates of P-glycoprotein can be further divided into drugs which are not metabolised in humans, such as digoxin, and those which are substrates of both P-glycoprotein and drugmetabolising enzymes, particularly CYP3A4.
2,3 As many P-glycoprotein substrates are also substrates of CYP3A4 and because P-glycoprotein inhibitors are also inhibitors of CYP3A4, many drug-drug interactions are related to inhibition or induction of both P-glycoprotein and CYP3A4. Drugs which are 'objects' of such interactions include cyclosporin, tacrolimus and rivaroxaban. 3 Enterocytes, like hepatocytes, simultaneously express the major drug-metabolising enzyme CYP3A4 and the efflux transporter P-glycoprotein. 7 This creates a drug efflux-metabolism 'alliance', which increases the exposure of the drug to metabolism by CYP3A4 through repeated cycles of absorption and efflux. 2 Modification of this active barrier function by concomitantly administered drugs contributes to altered absorption, increased interindividual differences in systemic drug concentrations and probably an increased risk of toxicity. 4 Accurate prediction of potential drug-drug interactions through P-glycoprotein is complicated by pronounced interindividual differences in bioavailability. This also affects drugs that are not metabolised in humans (fexofenadine, digoxin).
2,4 A better knowledge of the role of genetics in transporter expression and function will contribute to a better understanding of interindividual and interethnic differences in drug disposition and effects. 
SELF-TEST QUESTIONS
True or false?
5. Inhibitors of P-glycoprotein increase the oral bioavailability of its substrates.
6. P-glycoprotein metabolises dabigatran.
Answers on page 143
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interactions is important. Central nervous system depression, undertreated HIV infection and transplant rejection are all possible outcomes if these interactions occur. Knowledge of these potential
